
CHAMPIONING MEDICALLY INTEGRATED ONCOLOGY:
Celebrating
a Decade of Impact
2025 NCODA INTERNATIONAL
FALL SUMMIT

1


Myeloma:
From Current to Cutting Edge
Jordan Snyder, PharmD, BCOP
Clinical Hematology Pharmacist
University of Kansas Health System
2025 NCODA INTERNATIONAL
FALL SUMMIT
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

2


How to Claim Your CE Credit
For CE credit, please visit:
https://www.lecturepanda.com/r/2025NCODAFallSummit
Credit requirements must be completed within 60 days of the program activity date.
Upon completion, credit will be transmitted electronically to ACPE.
All transmitted credit will be viewable in your CPE Monitor profile within 24 hours.
CE codes will be displayed at the end of the presentation and will not be redistributed after this presentation.
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

3


OBJECTIVES
2025 NCODA INTERNATIONAL FALL SUMMIT
1. Discuss the role of quadruplet therapy in transplant-eligible and transplant-ineligible multiple myeloma and identify appropriate use in the frontline setting
2. Review chimeric antigen receptor (CAR) T-cell therapies' use in relapsed/refractory multiple myeloma
3. Summarize the role of BCMA-targeting bispecific antibodies in the management of relapsed/refractory multiple myeloma
4. Determine an evidence-based treatment plan for relapsed/refractory multiple myeloma with available sequencing data
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

4


DISCLOSURES
2025 NCODA INTERNATIONAL FALL SUMMIT
There are no relevant conflicts of interest to disclose for this presentation for the following speakers and planners:
• Jordan Snyder, PharmD, BCOP
• Tahsin Imam, PharmD
• Shawnny Eugene, PharmD
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

5


Multiple Myeloma
• Multiple myeloma is characterized by the abnormal proliferation of malignant plasma cells
• Accounts for 1% of all cancer diagnosis and 10% of all hematologic malignancies
• Median age at diagnosis is 65 years
• Occurs more commonly in men and African Americans
• Cause of nearly 13,000 deaths in the United States each year
Rajkumar S. Am J Hematol. 2024;99:1802-24.

6


Plasma Cell Disorder Spectrum
Monoclonal Gammopathy of Undetermined Significance (MGUS)
• Asymptomatic
• Increases risk of developing multiple myeloma at ~1% per year
Smoldering Myeloma
• Asymptomatic
• Increases risk of developing multiple myeloma at ~10% per year
Multiple Myeloma
• Rate of progression depends on cytogenetics and development of new mutations
Nieto MJ, et al. J Clin Haematol. 2023;4(1):35-42.
2025 NCODA INTERNATIONAL FALL SUMMIT

7


Quad Therapy in
Newly Diagnosed Myeloma
2025 NCODA INTERNATIONAL FALL SUMMIT

8


Doublets to Triplets
Trial | Population | Intervention | Outcomes | Impact
VISTA (2010) | NDMM, transplant ineligible (N=682) | VMP vs MP | •35% reduced risk of death at 3 years (HR 0.653, P<0.001) •3-year OS: 68.5% vs 54% | Addition of bortezomib significantly prolongs survival
GIMEMA-MMY-3006 (2012) | NDMM, transplant eligible (N=474) | VTD vs TD | •Median PFS: 60 months vs 41 months •10-year survival estimate: 34% vs 17% | Addition of bortezomib into double HSCT improved PFS and OS
SWOG S0777 (2017) | NDMM, without immediate HSCT (N=525) | VRD vs RD | •Median PFS: 43 mo vs 30 mo (HR 0.712, 95% CI 0.56-0.906; P=0.0018) •Median OS: 75 mo vs 64 mo (HR 0.709; 95% CI 0.524-0.959; P=0.025) | Triplet therapy became standard of care in NDMM
V: bortezomib; M: melphalan; P: prednisone; T: thalidomide; D: dexamethasone; R: lenalidomide; IMID: immunomodulator; mo: months, HR: hazard ratio, CI: confidence interval, PFS: progression free survival, OS: overall survival
Mateos MV, et al. J Clin Oncol. 2010;28(13):2259-2266. ; Facchetti P, et al. Lancet Haematol. 2020;7(12):e851-e873. ; Dunn BG, et al. The Lancet. 2017;389(10068):519-527.
2025 NCODA INTERNATIONAL FALL SUMMIT

9

Quad Therapies in Transplant Eligible

Trial	Population	Intervention	Outcomes	Impact
CASSIOPEIA (2019)	NDMM, transplant eligible (N=1085)	DaraVTD vs VTD with post HSCT consolidation and maintenance	•sCR at day 100: 29% vs 20% •Median PFS: NR in either group	Clinical benefits seen in induction, consolidation, and maintenance Less impact in US as RVD considered superior to VTD
GRIFFIN (2020)	NDMM, transplant eligible (N=207)	DaraRVD vs RVD with post HSCT consolidation and maintenance with DaraR or R	•ORR post-consolidation: 99% vs 91.8% (P=0.016) •4-year PFS: 87.2% vs 70% (HR 0.45; 95% CI 0.21-0.95; P=0.032) •Median OS: NR for both groups	Addition of dara to RVD resulted in higher response rates with deepening responses over time

Moreau P, et al. *Lancet*. 2019;394:29-38.; Moreau P, et al. *Lancet Oncol*. 2024;25(8):1003-1014.; Voorhees PM, et al. *Blood*. 2020;136(8):936-945.; Voorhees PM, et al. *Lancet Oncol*. 2023;10(10):E825-E837.

2025 NCODA INTERNATIONAL FALL SUMMIT

10

PERSEUS



*If MRD (-) at 24 months, daratumumab was discontinued

Sonneveld P, et al. *NEJM*. 2024;390:301-313.

2025 NCODA INTERNATIONAL FALL SUMMIT

11

PERSEUS – Patient Demographics

Baseline Characteristics	DaraRVd (n=355)	RVd (n=354)
Median Age, years (range)	61 (32-70)	59 (31-70)
Male, n (%)	211 (59.4)	205 (57.9)
Race, n (%) • White • Black	 330 (93) 5 (1.4)	 323 (91.2) 4 (1.1)
ECOG PS, n (%) • 0-1	 335 (94.3)	 338 (95.4)
Cytogenetic Risk, n (%) • Standard • High	 264 (74.4) 76 (21.4)	 266 (75.1) 78 (22)
Median time since diagnosis, months	1.2	1.1

PS: performance status

Sonneveld P, et al. *NEJM*. 2024;390:301-313.

2025 NCODA INTERNATIONAL FALL SUMMIT

12

PERSEUS – Results



	Dara-RVd (n=355)	RVd (n=354)
Overall Response, n (%)	343 (96.6)	332 (93.8)
MRD (-) Status, n (%) • 10^{-5} • 10^{-6}	 267 (75.2) 231 (65.1)	 168 (47.5) 114 (32.2)
Sustained MRD (-) for ≥ 12 months, n (%)	230 (64.8)	105 (29.7)
PFS at 48 months, % (95% CI)	84.3 (79.5-88.1)	67.7 (62.2-72.6)

PR: partial response, VGPR: very good partial response, CR: complete response, sCR: stringent complete response, MRD: minimal residual disease, PFS: progression free survival, CI: confidence interval

Slightly higher rates of adverse events in Dara-RVD arm vs. RVD arm including: cytopenias, infection, diarrhea, and infusion reactions

Sonneveld P, et al. NEJM. 2024;390:301-313.

2025 NCODA INTERNATIONAL FALL SUMMIT

13

Quad Therapy in Transplant-Ineligible

Trial	Population	Intervention	Outcomes	Impact
ALCYONE (2018)	NDMM, transplant ineligible (N=706)	DaraVMP vs VMP	• 18-month PFS: 71.6% vs 50.2% (HR 0.5; 95% CI 0.38-0.65; p<0.001) • ORR: 90.9% vs 73.9% (p<0.001)	Consideration for quad therapy growing Less impact in US as VRD considered superior to VMP

NDMM: newly diagnosed multiple myeloma, V: bortezomib, M: melphalan, P: prednisone, PFS: progression free survival, CI: confidence interval, ORR: overall response rate, R: lenalidomide

Mateos MV, et al. NEJM. 2018;378:518-528.

2025 NCODA INTERNATIONAL FALL SUMMIT

14

IMROZ



Facon T, et al. NEJM. 2024. DOI:10.1056/NEJMoa2400712

2025 NCODA INTERNATIONAL FALL SUMMIT

15

IMROZ – Patient Demographics

Baseline Characteristic	IsaRVd (n=265)	RVd (n=181)
Median Age, years (range)	72 (60-80)	72 (55-80)
Male, n (%)	143 (54)	94 (51.9)
Race • White • Black	 192 (72.5) 2 (0.8)	 131 (72.4) 2 (1.1)
ECOG PS • 0 - 1	 235 (88.7)	 162 (89.5)
Cytogenetic Risk • Standard • High	 207 (78.1) 40 (15.1)	 140 (77.3) 34 (18.8)
Median time since diagnosis, months	1.2	1.2

PS: performance status

Facon T, et al. *NEJM*. 2024; DOI:10.1056/NEJMoa2400712

2025 NCODA INTERNATIONAL FALL SUMMIT

16

IMROZ – Results



	IsaRVd (n=265)	RVd (n=181)
ORR, %	91.3	92.3
CR or better, %	74.7	64.1
60-month PFS, %	63.2	45.2
MRD- 10^{-5}, %	58.1	43.6
Estimated OS at 60 months, %	72.3	66.3

PR: partial response, VGPR: very good partial response, CR: complete response, sCR: stringent complete response, ORR: overall response rate, MRD: minimal residual disease, PFS: progression free survival, OS: overall survival

Slightly higher rates of adverse events with IsaRVd despite higher rates of discontinuation with RVd

Facon T, et al. *NEJM*. 2024; DOI:10.1056/NEJMoa2400712

2025 NCODA INTERNATIONAL FALL SUMMIT

17

BENEFIT



Leleu X, et al. *Nature Med*. 2024;30:2235-2241.

2025 NCODA INTERNATIONAL FALL SUMMIT

18

BENEFIT – Patient Demographics

Baseline Characteristic	IsaRVd (n=135)	IsaRd (n=135)
Median Age, years (IQR)	73.2 (71-76)	73.6 (71-76)
Male, n (%)	74 (55)	71 (53)
ECOG PS, n (%) • 0 or 1	125 (93)	119 (88)
Cytogenetic Risk, n (%) • Standard • High	68 (53) 13 (10)	75 (60) 10 (8)
Median time from diagnosis, months	1	0.9

PS: performance status

Leleu X, et al. *Nature Med.* 2024;30:2235-2241.

2025 NCODA INTERNATIONAL FALL SUMMIT

19

BENEFIT – Results



	IsaRVd (n=135)	IsaRd (n=135)
ORR, %	85	78
CR or better, %	58	31
24-month PFS, % (95% CI)	85.2 (79.2-91.7)	91.5 (86.5-96.8)
24-month OS, % (95% CI)	91.1 (86.1- 96.4)	80.0 (73.3- 87.4)

PR: partial response, VGPR: very good partial response, CR: complete response, ORR: overall response rate, PFS: progression free survival, CI: confidence interval, OS: overall survival

Slightly higher rates of adverse events with IsaRVd versus IsaRd including high rates of peripheral neuropathy

Leleu X, et al. *Nature Med.* 2024;30:2235-2241.

2025 NCODA INTERNATIONAL FALL SUMMIT

20

CEPHEUS



Usmani S, et al. *Nature Med.* 2025;31:1195-1202.

2025 NCODA INTERNATIONAL FALL SUMMIT

21

CEPHEUS – Patient Demographics

Baseline Characteristic	DaraRVd (N=197)	RVd (N=198)
Median Age, years (range)	70 (42-79)	70 (31-80)
Male, n (%)	87 (44)	111 (56.1)
Race, n (%) • White • Black	 162 (82.2) 10 (5.1)	 156 (78.8) 9 (4.5)
ECOG PS, n (%) • 0 -1	 174 (88.3)	 184 (92.9)
Cytogenetic Risk, n (%) • Standard • High	 149 (75.6) 25 (12.7)	 149 (75.3) 27 (13.6)
Median time since diagnosis, months	1.2	1.3

PS: performance status

Usmani S, et al. *Nature Med* 2025;31:1195-1202.

2025 NCODA INTERNATIONAL FALL SUMMIT

22

CEPHEUS – Results



	DaraRVd (n=135)	RVd (n=135)
≥ CR, %	81.2	61.6
MRD (-) rate, % • 10^{-5} • 10^{-6}	 60.9 46.2	 39.4 27.3
Median PFS, months	NR	52.6

PR: partial response, VGPR: very good partial response, CR: complete response, MRD: minimal residual disease, PFS: progression free survival

Slightly higher rates of adverse events with DaraRVd compared to RVd including: cytopenias, infection, pneumonia, injection site reactions

Usmani S, et al. *Nature Med* 2025;31:1195-1202.

2025 NCODA INTERNATIONAL FALL SUMMIT

23

Quad Therapy in Newly Diagnosed Myeloma

- Quad therapy has changed the landscape of newly diagnosed multiple myeloma
- Quad therapy showed higher rates of MRD-negativity and response rates in transplant-eligible and –ineligible myeloma
- Higher rates of adverse events were seen in patients receiving quad therapy, but did not impact outcomes

Sonneveld P, et al. *NEJM* 2024;390:301-313.; Facon T, et al. *NEJM* 2024; DOI:10.1056/NEJMoa2400712; Leleu X, et al. *Nature Med* 2024;30:2235-2241.;Usmani S, et al. *Nature Med* 2025;31:1195-1202.

24


QUESTION 1
2025 NCODA INTERNATIONAL FALL SUMMIT
PL is a 52-year-old male with a past medical history of hypertension and GERD. He presents in clinic with newly diagnosed multiple myeloma. ECOG PS is 0 and labs are unremarkable. He is deemed a transplant candidate. What is an appropriate 1st line regimen for PL?
a. IsaRVd
b. DaraRVd
c. RVd
d. DRd
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

25


CAR-T in Early Relapse
2025 NCODA INTERNATIONAL FALL SUMMIT

26


T-Cell Approvals in Multiple Myeloma
2021
Idecabtagene vicleucel
2022
Ciltacabtagene autoleucel
Teclistamab
2023
Elranatamab
Talquetamab
2024
Ciltacabtagene autoleucel: 2nd line
Idecabtagene vicleucel: 3rd line
2025
Linvoseltamab
FDA. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Updated March 22, 2024. Accessed September 19 2025. www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications
2025 NCODA INTERNATIONAL FALL SUMMIT

27

CAR-T in Late Relapse

Trial	Population	Intervention	Outcomes	Conclusions
KarMMa	Relapsed myeloma • Following ≥ 3 lines of therapy	Idecabtagene vicleucel	• ORR: 73% (95% CI: 66-81) • ≥ CR: 33% • mPFS: 8.8 months (95% CI: 5.6-11.6)	Ide-cel induced responses in heavily pre-treated patients with multiple myeloma
CARTITUDE-1	Relapsed myeloma • Following ≥ 3 lines of therapy	Ciltacabtagene autoleucel	• ORR: 97% (95 CI: 91.2-99.4) • sCR: 67% • 5-year PFS: 33% • mOS: 60.7 months (95% CI: 41.9-NE)	Early, deep, and durable responses were achieved in heavily pre-treated patients with cilta-cel

mPFS: median progression free survival; Ide-cel: idecabtagene vicleucel; CR: complete response; CI: confidence interval, mPFS: median progression free survival, mOS: median overall survival, NR: not reached; Cilta-cel: ciltacabtagene autoleucel; sCR: stringent complete response

Munshi NC, et al. *N Engl J Med* 2021;384:705-16; Berdeja JG, et al. *Lancet.* 2021;398(10307):314-24. Jagannath S, et al. *J Clin Oncol.* 2025;43:2766-71.

2025 NCODA INTERNATIONAL FALL SUMMIT

28

KarMMa-3

Relapsed/refractory multiple myeloma

2:1

Idecabtagene vicleucel (n=254)

Standard of care*(n=132)

	Ide-cel (n=254)	SOC (n=132)
Median age (range), years	63 (30-81)	63 (42-83)
Extramedullary disease, n (%)	61 (24)	32 (24)
High tumor burden, n (%)	71 (28)	34 (26)
High risk cytogenetics, n (%)	107 (42)	61 (46)
Median prior lines (range)	3 (2-4)	3 (2-4)
Previous autologous HSCT, n (%)	214 (84)	114 (86)
Triple-class refractory, n (%)	164 (65)	89 (67)

*Standard of care (SOC) regimens include: daratumumab, pomalidomide, dexamethasone; daratumumab, bortezomib, dexamethasone; ixazomib, lenalidomide, dexamethasone; carfilzomib, dexamethasone; elotuzumab, pomalidomide, dexamethasone

Rodriguez-Otero P, et al. *N Engl J Med.* 2023;388:1002-14.

2025 NCODA INTERNATIONAL FALL SUMMIT

29

KarMMa-3: Results

Overall Response Rates



	Ide-cel (n=254)	SOC (n=132)
Median PFS, mo (95% CI)*	13.3 (11.8-16.1)	4.4 (3.4-5.9)
6-month PFS, %	73	30
Median time to response, mo (range)	2.9 (0.5-13)	2.1 (0.9-9.4)
Median duration of response, mo (95% CI)	14.8 (12-18.6)	9.7 (5.4-16.3)

*p < 0.001; VGPR: very good partial response; sCR: stringent complete response; mo: months

Progression-free survival benefit with Ide-cel was seen across subgroups, including presence or absence of high-risk cytogenetics, high tumor burden, or triple-class refractory status

Rodriguez-Otero P, et al. *N Engl J Med.* 2023;388:1002-14.

2025 NCODA INTERNATIONAL FALL SUMMIT

30

KarMMa-3: Toxicity

	Ide-cel (n=250)	SOC (n=126)
CRS, n (%)	197 (88)	0 (0)
Neutropenia, n (%)	195 (78)	55 (44)
Anemia, n (%)	165 (66)	45 (36)
Infection, n (%)	146 (58)	68 (54)
Thrombocytopenia, n (%)	136 (54)	36 (29)
Nausea, n (%)	112 (45)	34 (27)
Diarrhea, n (%)	85 (34)	30 (24)
Neurotoxic event, n (%)	34 (15)	0 (0)

CRS: cytokine release syndrome

Median time to onset of CRS: 1 day (1-14 days)

Median duration of CRS: 3.5 days (1-51 days)

72% of patients receiving Ide-cel required tocilizumab for CRS

28% of patients receiving Ide-cel required corticosteroids for CRS

Median time to onset of neurotoxic event: 3 days (1-317 days)

Median duration of neurotoxic event: 2 days (1-37 days)

Ide-cel resulted in significantly longer PFS versus SOC regimens. These results were observed across subgroups and may benefit difficult to treat patients

Rodriguez-Otero P, et al. *N Engl J Med*. 2023;388:1002-14.

2025 NCODA INTERNATIONAL FALL SUMMIT

31

CARTITUDE-4

Relapsed/refractory multiple myeloma

1:1

Ciltacabtagene autoleucel (n=208)

Standard of care (SOC)* (n=211)

	Cilta-cel (n=208)	SOC (n=211)
Median age (range), years	61.5 (27-78)	61 (35-80)
Soft tissue plasmacytomas, n (%)	44 (21.2)	35 (16.6)
Bone marrow plasma cells > 60%, n (%)	42 (20.4)	43 (20.7)
High-risk cytogenetics, n (%)	123 (59.4)	132 (51)
Previous lines of therapy, n (%)		
1	68 (32.7)	68 (32.2)
2	83 (39.9)	87 (41.2)
3	57 (27.4)	56 (26.2)
Triple-class refractory, n (%)	30 (14.4)	33 (15.6)

*SOC regimens include: pomalidomide, bortezomib, dexamethasone; daratumumab, pomalidomide, dexamethasone

San-Miguel J, et al. *N Engl J Med*. 2023;389:335-47.

2025 NCODA INTERNATIONAL FALL SUMMIT

32

CARTITUDE-4: Results

Overall Response Rates



	Cilta-cel (n=208)	SOC (n=211)
Median time to response, mo (range)	2.1 (0.9-11.1)	1.2 (0.6-10.7)
Median time to best response, mo (range)	6.4 (1.1-18.6)	3.1 (0.8-20.6)
Minimal residual disease negative, n (%)	126 (60.6)	33 (15.6)
30-month PFS, %*	59.4	25.7
30-month OS, %	76.4	63.8

*p < 0.0001; VGPR: very good partial response; sCR: stringent complete response; mo: months; NR: not reached

PFS benefit with cilta-cel was seen across subgroups, including presence of high-risk cytogenetics and prior lines of therapy

Mateos M-V, et al. Presented at 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; San-Miguel J, et al. *N Engl J Med*. 2023;389:335-47.

2025 NCODA INTERNATIONAL FALL SUMMIT

33

CARTITUDE-4: Toxicity

	Cilta-cel (n=208)	SOC (n=126)
Neutropenia, n (%)	187 (89.9)	177 (85.1)
CRS, n (%)	134 (76.1)	0 (0)
Infection, n (%)	129 (62)	148 (71.2)
Anemia, n (%)	113 (54.3)	54 (26)
Thrombocytopenia, n (%)	113 (54.3)	65 (31.2)
Nausea, n (%)	101 (48.6)	38 (18.3)
Hypogammaglobulinemia, n (%)	88 (42.3)	13 (6.2)

CRS: cytokine release syndrome

Median time to CRS onset: 8 days (1-23 days)

Median duration of CRS: 3 days (1-17 days)

Cilta-cel had a favorable risk-benefit profile compared to standard of care. Due to the progression free survival benefit, cilta-cel is an option for patients on first relapse

San-Miguel J, et al. *N Engl J Med*. 2023;389:335-47.

2025 NCODA INTERNATIONAL FALL SUMMIT

34

CAR-T in Earlier Lines

	KarMMa-3	CARTITUDE-4
Median age, years (range)	63 (30-81)	61.5 (27-78)
High risk cytogenetics, n (%)	107 (42)	123 (59.4)
ORR, n (%)	181 (71)	176 (84.6)
PFS, months, (95% CI)	13.3 (11.8-16.1) (18.6-month follow-up)	NR (15.9-month follow-up)
Any grade adverse events, n (%)		
• Cytokine release syndrome	197 (88)	134 (76.1)
• Neutropenia	146 (58)	187 (89.9)
• Thrombocytopenia	136 (54)	113 (54.3)
• Infection	146 (58)	129 (62)
• Neurotoxic events	34 (15)	36 (20.5)

ORR: overall response rate, NR: not reached

Rodriguez-Otero P, et al. *N Engl J Med*. 2023;388:1002-14.; San-Miguel J, et al. *N Engl J Med*. 2023;389:335-47.

2025 NCODA INTERNATIONAL FALL SUMMIT

35

CAR-T in Relapsed/Refractory Myeloma

- CAR-T in earlier lines of therapy provides deep and durable remissions compared to standard of care chemotherapy
- May be an appropriate option in certain patients depending on performance and disease status
- No new safety signals identified when used in early relapse

Rodriguez-Otero P, et al. *N Engl J Med*. 2023;388:1002-14.; San-Miguel J, et al. *N Engl J Med*. 2023;389:335-47.

36

Bispecific T-Cell Engagers in Relapsed Myeloma

37

T-Cell Approvals in Multiple Myeloma



FDA. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Updated March 22, 2024. Accessed September 19 2025. www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notification

38

Bispecific T-Cell Engagers - Targets

BCMA
- Teclistamab
- Elranatamab
- Linvoseltamab

GPRC5D
- Talquetamab
- Forimtamig*

FcRH5
- Cevostamab*

*Available via investigational trial

Costa L, et al. *Leukemia*. 2025;39:543-54.

39

BCMA Bispecific T-Cell Engagers

Bispecific T-Cell Engager	Indication	Route	Maintenance Dosing	Hospitalization?	REMS
Teclistamab	Relapsed MM after 4 or more lines of therapy	SQ	• 1.5 mg/kg SQ once weekly x 6 months* • 1.5 mg/kg every 2 weeks	Yes – 48 hours after each step-up dose and first treatment dose	Yes
Elranatamab		SQ	• 76 mg SQ once weekly x 6 months • 76 mg SQ every 2 weeks x 6 months* • 76 mg SQ once monthly*	Yes – 48 hours after step-up dose 1 and 24 hours after step-up dose 2	Yes
Linvoseltamab		IV	• 200 mg IV once weekly weeks 4-13 • 200 mg IV every 2 weeks week 14-24 • 200 mg IV once monthly*	Yes – 24 hours after step-up dose 1 and 2	Yes

*In responders only. MM: multiple myeloma, SQ: subcutaneous, IV: intravenous

Tecvayli [Package Insert]. Horsham PA: Janssen Biotech. Updated: 8/2025. Elrexfio [Package Insert] New York, NY: Pfizer. Updated: 7/2025. Lynozyfic [Package Insert] Tarrytown, NY: Regeneron. Updated: 7/2025.

2025 NCODA INTERNATIONAL FALL SUMMIT

40

MAJESTEC-1

Relapsed Multiple Myeloma
- ≥ 18 years
- 3 prior lines of therapy
- No prior BCMA exposure

Teclistamab
- Target dose: 1.5 mg/kg SQ once weekly

Patient Characteristics	n=165
Median age (range), years	64 (33-84)
Soft tissue plasmacytomas, n (%)	28 (17)
High-risk cytogenetics, n / total n (%)	38/148 (15.5)
Median number of prior lines, n (range)	5 (2-14)
Refractory Status, n (%) • Triple-class • Penta-drug	128 (77.6) 50 (30.3)

Moreau P, et al. *N Engl J Med.* 2022; 387:495-505.

2025 NCODA INTERNATIONAL FALL SUMMIT

41

MAJESTEC-1 - Results



	n=165
VGPR or better, n (%)	97 (58.8)
Median PFS, months (95% CI)	11.3 (8.8-17.1)
Median OS, months (95% CI)	18.3 (15.1-NE)
Adverse Events	
Any Adverse Event, n (%)	165 (100)
Cytokine Release Syndrome, n (%)	119 (72.1)
Neutropenia, n (%)	117 (70.9)
Thrombocytopenia, n (%)	66 (40)
Pneumonia, n (%)	30 (18.2)
Neurotoxic Events, n (%)	24 (14.5)

Teclistamab provided deep and durable responses in a heavily pre-treated patient population

Moreau P, et al. *N Engl J Med.* 2022; 387:495-505.

2025 NCODA INTERNATIONAL FALL SUMMIT

42


MagnetisMM-3
Relapsed Multiple Myeloma
≥ 18 years
3 prior lines of therapy
No prior BCMA exposure
Elranatamab
Target dose: 76 mg SQ once weekly x6 cycles followed by 76 mg SQ every 2 weeks
Patient Characteristics | n=123
Median age (range), years | 68 (36-89)
Soft tissue plasmacytomas, n (%) | 28 (17)
High-risk cytogenetics, n (%) | 31 (25.2)
Median number of prior lines, n (range) | 5 (2-22)
Refractory Status, n (%)
Triple-class | 119 (96.7)
Penta-drug | 52 (42.3)
Lesokhin AM, et al. Nature Med 2023;29:2259-67.
2025 NCODA INTERNATIONAL FALL SUMMIT

43


MagnetisMM-3
Response Rate
Percentage of Patients
15.4
19.5
21.1
4.9
n=123
PR VGPR CR sCR
n=123
ORR, % (95% CI) | 61 (51.8-69.6)
VGPR or better, n (%) | 69 (56.1)
Median PFS, months (95% CI) | NE (9.9-NE)
Median OS, months (95% CI) | NE (13.9-NE)
Adverse Events
Any Adverse Event, n (%) | 123 (100)
Cytokine Release Syndrome, n (%) | 71 (57.7)
Neutropenia, n (%) | 60 (48.8)
Thrombocytopenia, n (%) | 38 (30.9)
Infection, n (%) | 86 (69.9)
ICANS, n (%) | 4 (3.4)
Elranatamab demonstrated durable responses that continued to deepen after the transition to biweekly dosing
Lesokhin AM, et al. Nature Med 2023;29:2259-67.
2025 NCODA INTERNATIONAL FALL SUMMIT

44


LINKER MM-1
Relapsed Multiple Myeloma
≥ 18 years
3 prior lines of therapy
No prior BCMA immunotherapies
Linvoseltamab
Target dose: 50 mg or 200 mg IV once weekly x 12 weeks followed by 200 mg IV every other week x 12 weeks followed by 200 mg IV once monthly
Patient Characteristics | 200 mg (n=117)
Median age (range), years | 70 (37-91)
Soft tissue plasmacytomas, n (%) | 19 (16.2)
High-risk cytogenetics, n (%) | 46 (39.3)
Median number of prior lines, n (range) | 5 (2-16)
Refractory Status, n (%)
Triple-class | 96 (82.1)
Penta-drug | 33 (28.2)
Bumma N, et al. J Clin Oncol 2024;42:2702-12.
2025 NCODA INTERNATIONAL FALL SUMMIT

45

LINKER MM-1

Response Rate



	n=117
ORR, %	70.9
VGPR or better, n (%)	74 (63.2)
Median PFS, months (95% CI)	NR (17.3-NE)
Median OS, months (95% CI)	NR (31.4-NE)
Adverse Events	
Any Adverse Event, n (%)	117 (100)
Cytokine Release Syndrome, n (%)	54 (46.2)
Anemia, n (%)	45 (38.5)
Thrombocytopenia, n (%)	38 (30.9)
Infection, n (%)	87 (74.4)
ICANS, n (%)	9 (7.7)

Linvoseltamab offers clinical benefit in a high risk, heavily pre-treated population and increases patient convenience with less frequent dosing

Bumma N, et al. *J Clin Oncol* 2024;42:2702-12.

2025 NCODA INTERNATIONAL FALL SUMMIT

46

BCMA Bispecific T-Cell Engagers

Bispecific T-cell Engager	ORR	≥ VGPR	PFS	CRS Rate		ICANS Rate	
				All Grades	≥ Grade 3	All Grades	≥ Grade 3
Teclistamab	63%	58.8%	11.3 mo (14.1 mo follow up)	72.1%	0.6%	14.5%	0.6%
Elranatamab	61%	56.1%	NR (14.7 mo follow up)	71%	0	3.4%	0
Linvoseltamab	70.9%	63.2%	NR (14.3 mo follow up)	46.2%	0.9%	7.7%	2.6%

Moreau P, et al. *N Engl J Med* 2022; 387:495-505. Lesokhin AM, et al. *Nature Med* 2023;29:2259-67.; Bumma N, et al. *J Clin Oncol* 2024;42:2702-12.

2025 NCODA INTERNATIONAL FALL SUMMIT

47

QUESTION 2

2025 NCODA INTERNATIONAL FALL SUMMIT

PL completed induction with Dara-RVd and completed as autologous stem cell transplant. He is currently on daratumumab + lenalidomide maintenance. During his 1-year work up, his bone marrow biopsy showed 30% monoclonal plasma cells.

What is an appropriate 2nd line therapy?

a. Teclistamab
b. Ide-cel
c. Cilta-cel
d. DRd

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

48

Sequencing BCMA Agents

- BCMA-targeting agents have changed the management of relapsed/refractory multiple myeloma
- Several BCMA-targeting agents available including: cilta-cel, ide-cel, teclistamab, elranatamab, linvoseltamab, belantamab (via clinical trial or compassionate use)
- Concerns with T-cell exhaustion and development of resistance are growing concerns with repeated BCMA-targeting agents
- With access to several agents, optimal sequencing while important, is still yet to be determined

Dimopoulos M, et al. ASCO Daily News. Sequencing Anti-BCMA Therapies in Multiple Myeloma: What Is Their Optimal Use with Other Available Treatment Options? 12/2024. Accessed 9/18/2025. https://dailynews.ascopubs.org/do/sequencing-anti-bcma-therapies-multiple-myeloma-their-optimal-use-other-available. Quach H. *Blood*. 2024;144(23):2365-67.

49

CARTITUDE-2 Cohort C

Evaluation of cilta-cel in BCMA-exposed relapsed/refractory myeloma

	All (n=20)	Prior ADC (n=13)	Prior BsAb (n=7)
Median age (range), years	62.5 (44-81)	66 (44-81)	60 (49-71)
High-risk cytogenetics, n (%)	3 (15)	2 (15.4)	1 (14.3)
Median prior lines, n (range)	8 (4-13)	8 (4-13)	8 (6-12)
Penta drug refractory, n (%)	11 (55)	7 (53.8)	4 (57.1)
Anti-BCMA refractory, n (%)	16 (80)	11 (84.6)	5 (71.4)

Time from last anti-BCMA to cilta-cel infusion: 62-944 days

Duration of prior anti-BCMA: 1-527 days

Cohen AD, et al. *Blood*. 2023;141(3):219-230.

2025 NCODA INTERNATIONAL FALL SUMMIT

50

CARTITUDE-2 Cohort C - Results

	All (n=20)	Prior ADC (n=13)	Prior BsAb (n=7)
ORR, % (95% CI)	60 (36.1-80.9)	61.5 (431.6-86.1)	57.1 (18.4-90.1)
MRD (-) 10-5, %	35	39	28
Median DOR, months (95% CI)	11.5 (7.9-NE)	11.5 (7.9-NE)	8.2 (4.4-NE)
Median PFS, months (95% CI)	9.1 (1.5-NE)	9.5 (0.99-NE)	5.3 (0.6-NE)

Patients more likely to respond if:
- Shorter duration of prior BCMA agent
- Longer time between cilta-cel and prior BCMA agent

Results suggest response after prior BCMA studies, larger prospective trials are needed for a better understanding of sequencing

No additional safety concerns identified

Cohen AD, et al. *Blood*. 2023;141(3):219-230.

2025 NCODA INTERNATIONAL FALL SUMMIT

51


Response with Bispecific T-cell Engagers After Prior BCMA Agents
MajesTEC-1
Teclistamab
• 40 patients with prior BCMA
• ORR 52.5%
• ADC: 55.2%
• CAR-T: 53.3%
• 30% with CR or better
MagnetisMM
Elranatamab
• 86 patients with prior BCMA
• ORR = 45.3%
• ADC: 41.4%
• CAR-T: 52.8%
• 17.4% achieved CR or better
Linker MM-1
Linvoseltamab
• 10 patients with prior BCMA ADC
• ORR 70%
2025 NCODA INTERNATIONAL FALL SUMMIT

52


Guidance for Sequencing
• Growing area of research, but available studies have small cohorts of patients
• Although a response may occur, overall response rates are lower than seen in BCMA-naïve patients
• A longer time between BCMA targeting agents may increase the chance of response
• Sequencing in the real-world may be depending on patient factors and availability of treatments

53


Future Directions
• Optimization of CAR-T therapies – dual targeting, allogeneic CAR-T products, new targets
• Combination therapies with bispecific T-cell engagers and use in earlier lines of therapy
• Emergence of MRD (-) guided treatment decisions
• Trispecific antibodies currently under investigation
• Increasing access to novel therapies in the community

54


QUESTION 3
2025 NCODA INTERNATIONAL FALL SUMMIT
RT is a 71-year-old female with relapsed/refractory multiple myeloma. She has a past medical history of treatment-related peripheral neuropathy, hypothyroidism, and hypertension. She has previously received Dara-RVd, HSCT, Daratumumab/lenalidomide maintenance, KPd, DPd, and most recently cilta-cel (currently day +180). She is now progressing.
What would be an appropriate next line of therapy?
a. Elranatamab
b. Talquetamab
c. CyBorD
d. Belantamab
e. a or b
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

55


SUMMARY
2025 NCODA INTERNATIONAL FALL SUMMIT
Landscape of multiple myeloma treatment is rapidly evolving
Quad therapies have become the main stay in treatment of transplant-eligible and –ineligible newly diagnosed multiple myeloma
The use of t-cell redirecting therapies are highly active in multiple myeloma and are continuing to be investigation in combination and in earlier lines of therapy
BCMA-targeting agents are effective in a heavily pre-treated patient population, but optimal sequencing is still under investigation
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

56


QUESTION & ANSWER
2025 NCODA INTERNATIONAL FALL SUMMIT
Myeloma:
From Current to Cutting Edge
Jordan Snyder, PharmD, BCOP
Clinical Hematology Pharmacist
University of Kansas Health System
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

57


CE CODE
2025 NCODA INTERNATIONAL
FALL SUMMIT
Myeloma:
From Current to Cutting Edge
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

58